Clene INC Form 4 insider transactions

Director Matthew Kiernan acquired stock options for 2,886 shares of Clene Inc. common stock on February 27, 2025.

Director Vallerie McLaughlin receives stock options for 3,175 shares of Clene Inc. common stock.

Director David J. Matlin reports acquisition of stock options in Clene Inc.

Director Jacobovitz Shalom reports the acquisition of stock options in Clene Inc.

Director Jonathon Gay acquired 3,716 stock options in Clene Inc. on February 27, 2025, according to a Form 4 filing.

Director Arjun Desai acquired 3,319 stock options in Clene Inc. on February 27, 2025, according to a Form 4 filing.

Clene Inc.'s CEO, Robert Dee Etherington, reports the acquisition of 45,000 stock options in the company, as per a Form 4 filing with the SEC.

Mark Mortenson, Chief Science Officer of Clene Inc., reports the grant of stock options for 40,000 shares of common stock.

Clene Inc.'s Chief Financial Officer, Morgan R. Brown, was granted 20,000 stock options on February 24, 2025, according to a Form 4 filing with the SEC.

Director Vallerie McLaughlin was granted stock options for 3,138 shares of Clene Inc. common stock at an exercise price of $4.40 per share.

Clene Inc. director Arjun Desai was granted stock options for 3,280 shares of common stock at an exercise price of $4.40 per share.

Director Shalom Jacobovitz of Clene Inc. was granted stock options for 4,243 shares of common stock at an exercise price of $4.40 per share.

Clene Inc. director Jonathon Gay was granted stock options for 3,673 shares of common stock at an exercise price of $4.40 per share.

Director David J. Matlin of Clene Inc. was granted stock options for 5,563 shares of common stock at an exercise price of $4.40 per share.

Director Alison Mosca of Clene Inc. was granted stock options for 4,350 shares of common stock at an exercise price of $4.40 per share.

Director Reed N. Wilcox of Clene Inc. was granted stock options for 2,853 shares of common stock at an exercise price of $4.40 per share.

Clene Inc. director Matthew Kiernan was granted stock options for 2,853 shares of common stock at an exercise price of $4.40 per share.

Director Vallerie McLaughlin acquired 2,815 stock options in Clene Inc. on October 2, 2024, at an exercise price of $4.89 per share, which vest immediately.

Director Arjun Desai acquired 2,943 stock options in Clene Inc. on October 2, 2024, vesting immediately.

Director Jonathon Gay of Clene Inc. reports the acquisition of stock options for 3,295 shares of common stock.

Director Alison Mosca reports acquisition of stock options in Clene Inc.

Director David J. Matlin reports acquisition of stock options in Clene Inc.

Director Matthew Kiernan acquired 2,559 stock options in Clene Inc. on October 2, 2024, vesting immediately.

Director Jacobovitz Shalom acquired stock options for 3,806 shares of Clene Inc. common stock on October 2, 2024.

Director Reed N. Wilcox acquired 2,559 stock options in Clene Inc. on October 2, 2024, vesting immediately.

Alison Mosca, a director of Clene Inc., reported acquiring shares and warrants, along with adjustments to previously held shares due to a reverse stock split.

Director Chidozie Ugwumba reports acquisition of warrants in Clene Inc. through Symbiosis II, LLC.

Director David J. Matlin reports acquisition of Clene Inc. shares and warrants, increasing his direct and indirect holdings.

Clene Inc.'s Chief Science Officer, Mark Mortenson, recently acquired shares and warrants of the company's common stock.

Clene Inc.'s CEO, Robert Dee Etherington, reports the acquisition of 10,000 shares of common stock and 10,000 warrants.